{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T11:48:35Z","timestamp":1783424915664,"version":"3.54.6"},"reference-count":70,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","interventional.theclinics.com","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Interventional Cardiology Clinics"],"published-print":{"date-parts":[[2024,10]]},"DOI":"10.1016\/j.iccl.2024.06.003","type":"journal-article","created":{"date-parts":[[2024,8,3]],"date-time":"2024-08-03T20:25:39Z","timestamp":1722716739000},"page":"483-491","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["High Bleeding Risk in Patients Undergoing Coronary and Structural Heart Interventions"],"prefix":"10.1016","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3909-182X","authenticated-orcid":false,"given":"Mattia","family":"Galli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Domenico","family":"D\u2019Amario","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"23","key":"10.1016\/j.iccl.2024.06.003_bib1","doi-asserted-by":"crossref","first-page":"2187","DOI":"10.1056\/NEJMoa1103510","article-title":"Transcatheter versus surgical aortic-valve replacement in high-risk patients","volume":"364","author":"Smith","year":"2011","journal-title":"N\u00a0Engl J Med"},{"issue":"17","key":"10.1016\/j.iccl.2024.06.003_bib2","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1056\/NEJMoa1008232","article-title":"Transcatheter aortic-valve implantation for aortic stenosis in patients who cannot undergo surgery","volume":"363","author":"Leon","year":"2010","journal-title":"N\u00a0Engl J Med"},{"issue":"10388","key":"10.1016\/j.iccl.2024.06.003_bib3","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1016\/S0140-6736(23)00459-2","article-title":"Current concepts in coronary artery revascularisation","volume":"401","author":"Gaudino","year":"2023","journal-title":"Lancet (London, England)"},{"issue":"15","key":"10.1016\/j.iccl.2024.06.003_bib4","first-page":"1379","article-title":"Fibrinolysis or Primary PCI in ST-Segment Elevation Myocardial Infarction","volume":"368","author":"Armstrong","year":"2013"},{"issue":"16","key":"10.1016\/j.iccl.2024.06.003_bib5","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1161\/CIRCULATIONAHA.121.054305","article-title":"Antithrombotic therapy in patients undergoing transcatheter interventions for structural heart disease","volume":"144","author":"Calabr\u00f2","year":"2021","journal-title":"Circulation"},{"issue":"17","key":"10.1016\/j.iccl.2024.06.003_bib6","doi-asserted-by":"crossref","first-page":"e1371","DOI":"10.4244\/EIJ-D-21-00904","article-title":"Antiplatelet therapy after percutaneous coronary intervention","volume":"17","author":"Angiolillo","year":"2022","journal-title":"EuroIntervention"},{"issue":"13","key":"10.1016\/j.iccl.2024.06.003_bib7","doi-asserted-by":"crossref","first-page":"723","DOI":"10.2217\/pgs-2022-0057","article-title":"Precision medicine in interventional cardiology: implications for antiplatelet therapy in patients undergoing percutaneous coronary intervention","volume":"23","author":"Galli","year":"2022","journal-title":"Pharmacogenomics"},{"issue":"2","key":"10.1016\/j.iccl.2024.06.003_bib8","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1038\/s41569-021-00598-1","article-title":"Bleeding avoidance strategies in percutaneous coronary intervention","volume":"19","author":"Capodanno","year":"2022","journal-title":"Nat Rev Cardiol"},{"key":"10.1016\/j.iccl.2024.06.003_bib9","doi-asserted-by":"crossref","first-page":"975969","DOI":"10.3389\/fcvm.2022.975969","article-title":"De-escalation of antiplatelet therapy in acute coronary syndromes: Why, how and when?","volume":"9","author":"Galli","year":"2022","journal-title":"Frontiers in cardiovascular medicine"},{"issue":"8","key":"10.1016\/j.iccl.2024.06.003_bib10","article-title":"Bleeding complications in patients undergoing percutaneous coronary intervention","volume":"23","author":"Galli","year":"2022"},{"issue":"12","key":"10.1016\/j.iccl.2024.06.003_bib11","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1080\/14740338.2023.2291865","article-title":"Bleeding in acute coronary syndrome: from definitions, incidence, and prognosis to prevention and management","volume":"22","author":"Laudani","year":"2023","journal-title":"Expet Opin Drug Saf"},{"issue":"11","key":"10.1016\/j.iccl.2024.06.003_bib12","first-page":"804","article-title":"Trade-off of myocardial infarction vs. bleeding types on mortality after acute coronary syndrome: lessons from the Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRACER) randomized trial","volume":"38","author":"Valgimigli","year":"2017","journal-title":"Eur Heart J"},{"issue":"23","key":"10.1016\/j.iccl.2024.06.003_bib13","doi-asserted-by":"crossref","first-page":"2736","DOI":"10.1161\/CIRCULATIONAHA.110.009449","article-title":"Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the Bleeding Academic Research Consortium","volume":"123","author":"Mehran","year":"2011","journal-title":"Circulation"},{"issue":"10","key":"10.1016\/j.iccl.2024.06.003_bib14","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1056\/NEJM199309023291001","article-title":"An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction","volume":"329","year":"1993","journal-title":"N\u00a0Engl J Med"},{"issue":"4","key":"10.1016\/j.iccl.2024.06.003_bib15","doi-asserted-by":"crossref","first-page":"256","DOI":"10.7326\/0003-4819-115-4-256","article-title":"Hemorrhagic events during therapy with recombinant tissue-type plasminogen activator, heparin, and aspirin for acute myocardial infarction. Results of the Thrombolysis in Myocardial Infarction (TIMI), Phase II Trial","volume":"115","author":"Bovill","year":"1991","journal-title":"Ann Intern Med"},{"issue":"1","key":"10.1016\/j.iccl.2024.06.003_bib16","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1161\/01.CIR.76.1.142","article-title":"Thrombolysis in Myocardial Infarction (TIMI) Trial, Phase I: A comparison between intravenous tissue plasminogen activator and intravenous streptokinase. Clinical findings through hospital discharge","volume":"76","author":"Chesebro","year":"1987","journal-title":"Circulation"},{"issue":"4","key":"10.1016\/j.iccl.2024.06.003_bib17","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1111\/j.1538-7836.2005.01204.x","article-title":"Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients","volume":"3","author":"Schulman","year":"2005","journal-title":"J\u00a0Thromb Haemostasis"},{"issue":"21","key":"10.1016\/j.iccl.2024.06.003_bib18","first-page":"2717","article-title":"Valve academic research consortium 3","volume":"77","author":"G\u00e9n\u00e9reux","year":"2021","journal-title":"Updated Endpoint Definitions for Aortic Valve Clinical Research"},{"issue":"18","key":"10.1016\/j.iccl.2024.06.003_bib19","doi-asserted-by":"crossref","first-page":"2135","DOI":"10.1016\/j.jacc.2016.02.056","article-title":"Validation of BARC bleeding criteria in patients with acute coronary syndromes: The TRACER trial","volume":"67","author":"Vranckx","year":"2016","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"11","key":"10.1016\/j.iccl.2024.06.003_bib20","first-page":"1424","article-title":"Validation of the bleeding academic research consortium definition of bleeding in patients with coronary artery disease undergoing percutaneous coronary intervention","volume":"125","author":"Ndrepepa","year":"2012"},{"issue":"6","key":"10.1016\/j.iccl.2024.06.003_bib21","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1093\/ehjacc\/zuad051","article-title":"The evaluation and management of coagulopathies in the intensive therapy units","volume":"12","author":"Galli","year":"2023","journal-title":"Eur Heart J Acute Cardiovasc Care"},{"issue":"9","key":"10.1016\/j.iccl.2024.06.003_bib22","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1016\/j.jacc.2015.06.1323","article-title":"Incidence, predictors, and impact of post-discharge bleeding after percutaneous coronary intervention","volume":"66","author":"G\u00e9n\u00e9reux","year":"2015","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.iccl.2024.06.003_bib23","first-page":"131424","article-title":"\"Ticking away the moments that make up a dull DAPT course\": Time matters","author":"Galli","year":"2023","journal-title":"Int J Cardiol"},{"issue":"2","key":"10.1016\/j.iccl.2024.06.003_bib24","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1093\/ehjcvp\/pvad085","article-title":"Impact of ethnicity on antiplatelet treatment regimens for bleeding reduction in acute coronary syndromes: a systematic review and pre-specified subgroup meta-analysis","volume":"10","author":"Galli","year":"2023","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"issue":"1","key":"10.1016\/j.iccl.2024.06.003_bib25","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1093\/ehjcvp\/pvz031","article-title":"Antithrombotic therapy in the early phase of non-ST-elevation acute coronary syndromes: a systematic review and meta-analysis","volume":"6","author":"Galli","year":"2020","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"issue":"2","key":"10.1016\/j.iccl.2024.06.003_bib26","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1161\/CIRCULATIONAHA.120.046786","article-title":"Comparative efficacy and safety of oral P2Y(12) inhibitors in acute coronary syndrome: network meta-analysis of 52 816 patients from 12 randomized trials","volume":"142","author":"Navarese","year":"2020","journal-title":"Circulation"},{"issue":"10","key":"10.1016\/j.iccl.2024.06.003_bib27","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1093\/eurheartj\/ehab836","article-title":"Comparative effects of guided vs. potent P2Y12 inhibitor therapy in acute coronary syndrome: a network meta-analysis of 61 898 patients from 15 randomized trials","volume":"43","author":"Galli","year":"2022","journal-title":"Eur Heart J"},{"key":"10.1016\/j.iccl.2024.06.003_bib28","first-page":"h1618","article-title":"Optimal duration of dual antiplatelet therapy after percutaneous coronary intervention with drug eluting stents: meta-analysis of randomised controlled trials","volume":"350","author":"Navarese","year":"2015","journal-title":"BMJ (Clinical research ed)"},{"issue":"2","key":"10.1016\/j.iccl.2024.06.003_bib29","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1093\/ehjcvp\/pvaa001","article-title":"Very short vs. long dual antiplatelet therapy after second generation drug-eluting stents in 35 785 patients undergoing percutaneous coronary interventions: a meta-analysis of randomized controlled trials","volume":"7","author":"Benenati","year":"2021","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"10.1016\/j.iccl.2024.06.003_bib30","first-page":"100524","article-title":"Randomised trials and meta-analyses of double vs triple antithrombotic therapy for atrial fibrillation-ACS\/PCI: A critical appraisal","volume":"28","author":"Galli","year":"2020","journal-title":"Int J Cardiol Heart Vasc"},{"issue":"37","key":"10.1016\/j.iccl.2024.06.003_bib31","doi-asserted-by":"crossref","first-page":"3512","DOI":"10.1093\/eurheartj\/ehac294","article-title":"Great Debate: Triple antithrombotic therapy in patients with atrial fibrillation undergoing coronary stenting should be limited to 1 week","volume":"43","author":"De Caterina","year":"2022","journal-title":"Eur Heart J"},{"issue":"6","key":"10.1016\/j.iccl.2024.06.003_bib32","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1161\/CIRCULATIONAHA.118.036248","article-title":"Major bleeding rates in atrial fibrillation patients on single, dual, or triple antithrombotic therapy","volume":"139","author":"van Rein","year":"2019","journal-title":"Circulation"},{"issue":"10","key":"10.1016\/j.iccl.2024.06.003_bib33","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1161\/CIRCULATIONAHA.112.114967","article-title":"Bleeding after initiation of multiple antithrombotic drugs, including triple therapy, in atrial fibrillation patients following myocardial infarction and coronary intervention: a nationwide cohort study","volume":"126","author":"Lamberts","year":"2012","journal-title":"Circulation"},{"issue":"4","key":"10.1016\/j.iccl.2024.06.003_bib34","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1093\/europace\/euz345","volume":"22","author":"Galli","year":"2020","journal-title":"Europace"},{"issue":"7","key":"10.1016\/j.iccl.2024.06.003_bib35","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1016\/j.jacc.2022.11.050","article-title":"Bleeding events after transcatheter aortic valve replacement: JACC state-of-the-art review","volume":"81","author":"Avvedimento","year":"2023","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"14","key":"10.1016\/j.iccl.2024.06.003_bib36","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1016\/j.jcin.2017.04.034","article-title":"Frequency, timing, and impact of access-site and non-access-site bleeding on mortality among patients undergoing transcatheter aortic valve replacement","volume":"10","author":"Piccolo","year":"2017","journal-title":"JACC Cardiovasc Interv"},{"issue":"25","key":"10.1016\/j.iccl.2024.06.003_bib37","doi-asserted-by":"crossref","first-page":"2317","DOI":"10.1016\/j.jacc.2012.02.022","article-title":"Clinical outcomes after transcatheter aortic valve replacement using valve academic research consortium definitions: a weighted meta-analysis of 3,519 patients from 16 studies","volume":"59","author":"G\u00e9n\u00e9reux","year":"2012","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"3","key":"10.1016\/j.iccl.2024.06.003_bib38","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1093\/ehjcvp\/pvad003","article-title":"Antithrombotic therapy and cardiovascular outcomes after transcatheter aortic valve implantation in patients without indications for chronic oral anticoagulation: a systematic review and network meta-analysis of randomized controlled trials","volume":"9","author":"Guedeney","year":"2023","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"issue":"18","key":"10.1016\/j.iccl.2024.06.003_bib39","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.1161\/CIRCULATIONAHA.120.050117","article-title":"Primary outcome evaluation of a next-generation left atrial appendage closure device: results from the PINNACLE FLX Trial","volume":"143","author":"Kar","year":"2021","journal-title":"Circulation"},{"issue":"19","key":"10.1016\/j.iccl.2024.06.003_bib40","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1161\/CIRCULATIONAHA.121.057063","article-title":"Amplatzer Amulet left atrial appendage occluder versus watchman device for stroke prophylaxis (Amulet IDE): a randomized, controlled trial","volume":"144","author":"Lakkireddy","year":"2021","journal-title":"Circulation"},{"issue":"4","key":"10.1016\/j.iccl.2024.06.003_bib41","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.jacc.2021.04.098","article-title":"Predictors of device-related thrombus following percutaneous left atrial appendage occlusion","volume":"78","author":"Simard","year":"2021","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"9","key":"10.1016\/j.iccl.2024.06.003_bib42","doi-asserted-by":"crossref","first-page":"774","DOI":"10.4244\/EIJ-D-20-01309","article-title":"Incidence and clinical impact of major bleeding following left atrial appendage occlusion: insights from the Amplatzer Amulet Observational Post-Market Study","volume":"17","author":"Aminian","year":"2021","journal-title":"EuroIntervention"},{"issue":"15","key":"10.1016\/j.iccl.2024.06.003_bib43","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.1016\/j.jcin.2015.08.035","article-title":"Bleeding outcomes after left atrial appendage closure compared with long-term warfarin: a pooled, patient-level analysis of the WATCHMAN randomized trial experience","volume":"8","author":"Price","year":"2015","journal-title":"JACC Cardiovasc Interv"},{"issue":"7","key":"10.1016\/j.iccl.2024.06.003_bib44","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1016\/j.jcin.2022.02.009","article-title":"Clinical outcomes at 1 year following transcatheter left atrial appendage occlusion in the United States","volume":"15","author":"Price","year":"2022","journal-title":"JACC Cardiovasc Interv"},{"issue":"5","key":"10.1016\/j.iccl.2024.06.003_bib45","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1016\/j.jacep.2023.02.007","article-title":"Left atrial appendage occlusion in the elderly: insights from PROTECT-AF, PREVAIL, and continuous access registries","volume":"9","author":"Sulaiman","year":"2023","journal-title":"JACC Clinical electrophysiology"},{"issue":"4","key":"10.1016\/j.iccl.2024.06.003_bib46","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/j.jacc.2020.11.046","article-title":"Prognostic implications of declining hemoglobin content in patients hospitalized with acute coronary syndromes","volume":"77","author":"Leonardi","year":"2021","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.iccl.2024.06.003_bib47","doi-asserted-by":"crossref","DOI":"10.1093\/eurheartj\/ehad191","article-title":"2023 ESC Guidelines for the management of acute coronary syndromes: Developed by the task force on the management of acute coronary syndromes of the European Society of Cardiology (ESC)","author":"Byrne","year":"2023","journal-title":"Eur Heart J"},{"issue":"14","key":"10.1016\/j.iccl.2024.06.003_bib48","doi-asserted-by":"crossref","first-page":"1873","DOI":"10.1161\/CIRCULATIONAHA.108.828541","article-title":"Baseline risk of major bleeding in non-ST-segment-elevation myocardial infarction: the CRUSADE (Can Rapid risk stratification of Unstable angina patients Suppress ADverse outcomes with Early implementation of the ACC\/AHA Guidelines) Bleeding Score","volume":"119","author":"Subherwal","year":"2009","journal-title":"Circulation"},{"issue":"12","key":"10.1016\/j.iccl.2024.06.003_bib49","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1016\/j.hlc.2020.04.008","article-title":"Meta-analysis of bleeding scores performance for acute coronary syndrome","volume":"29","author":"Wang","year":"2020","journal-title":"Heart Lung Circ"},{"issue":"23","key":"10.1016\/j.iccl.2024.06.003_bib50","doi-asserted-by":"crossref","first-page":"2556","DOI":"10.1016\/j.jacc.2009.09.076","article-title":"A\u00a0risk score to predict bleeding in patients with acute coronary syndromes","volume":"55","author":"Mehran","year":"2010","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"5","key":"10.1016\/j.iccl.2024.06.003_bib51","first-page":"e012157","article-title":"Development and validation of a novel risk score for in-hospital major bleeding in acute myocardial infarction:\u2014The SWEDEHEART Score","volume":"8","author":"Simonsson","year":"2019"},{"key":"10.1016\/j.iccl.2024.06.003_bib52","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.ijcard.2017.10.103","article-title":"Development and external validation of a post-discharge bleeding risk score in patients with acute coronary syndrome: The BleeMACS score","volume":"254","author":"Raposeiras-Roub\u00edn","year":"2018","journal-title":"Int J Cardiol"},{"issue":"19","key":"10.1016\/j.iccl.2024.06.003_bib53","doi-asserted-by":"crossref","first-page":"2224","DOI":"10.1016\/j.jacc.2016.02.064","article-title":"Coronary thrombosis and major bleeding after PCI with drug-eluting stents: risk scores from PARIS","volume":"67","author":"Baber","year":"2016","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"16","key":"10.1016\/j.iccl.2024.06.003_bib54","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1001\/jama.2016.3775","article-title":"Development and validation of a prediction rule for benefit and harm of dual antiplatelet therapy beyond 1 year after percutaneous coronary intervention","volume":"315","author":"Yeh","year":"2016","journal-title":"JAMA"},{"issue":"10073","key":"10.1016\/j.iccl.2024.06.003_bib55","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1016\/S0140-6736(17)30397-5","article-title":"Derivation and validation of the predicting bleeding complications in patients undergoing stent implantation and subsequent dual antiplatelet therapy (PRECISE-DAPT) score: a pooled analysis of individual-patient datasets from clinical trials","volume":"389","author":"Costa","year":"2017","journal-title":"Lancet (London, England)"},{"issue":"7","key":"10.1016\/j.iccl.2024.06.003_bib56","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1016\/j.jacc.2018.11.048","article-title":"Dual antiplatelet therapy duration based on ischemic and bleeding risks after coronary stenting","volume":"73","author":"Costa","year":"2019","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"8","key":"10.1016\/j.iccl.2024.06.003_bib57","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1093\/ehjcvp\/pvad063","article-title":"External validity of the PRECISE-DAPT score in patients undergoing PCI: a systematic review and meta-analysis","volume":"9","author":"Munaf\u00f2","year":"2023","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"issue":"3","key":"10.1016\/j.iccl.2024.06.003_bib58","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1161\/CIRCULATIONAHA.119.040167","article-title":"Defining high bleeding risk in patients undergoing percutaneous coronary intervention","volume":"140","author":"Urban","year":"2019","journal-title":"Circulation"},{"issue":"14","key":"10.1016\/j.iccl.2024.06.003_bib59","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.4244\/EIJV16I14A202","article-title":"Consolidating the value of the standardised ARC-HBR definition","volume":"16","author":"Gargiulo","year":"2021","journal-title":"EuroIntervention"},{"issue":"5","key":"10.1016\/j.iccl.2024.06.003_bib60","doi-asserted-by":"crossref","first-page":"371","DOI":"10.4244\/EIJ-D-20-00052","article-title":"Validation of the Academic Research Consortium for High Bleeding Risk (ARC-HBR) criteria in patients undergoing percutaneous coronary intervention and comparison with contemporary bleeding risk scores","volume":"16","author":"Ueki","year":"2020","journal-title":"EuroIntervention"},{"issue":"38","key":"10.1016\/j.iccl.2024.06.003_bib61","doi-asserted-by":"crossref","first-page":"3743","DOI":"10.1093\/eurheartj\/ehaa671","article-title":"Validation of high bleeding risk criteria and definition as proposed by the academic research consortium for high bleeding risk","volume":"41","author":"Corpataux","year":"2020","journal-title":"Eur Heart J"},{"issue":"4","key":"10.1016\/j.iccl.2024.06.003_bib62","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1001\/jamacardio.2020.6814","article-title":"Assessing the risks of bleeding vs thrombotic events in patients at high bleeding risk after coronary stent implantation: the ARC\u2013high bleeding risk trade-off model","volume":"6","author":"Urban","year":"2021","journal-title":"JAMA cardiology"},{"issue":"9","key":"10.1016\/j.iccl.2024.06.003_bib63","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1016\/j.jcin.2020.01.238","article-title":"Frailty and bleeding in older adults undergoing TAVR or SAVR: Insights From the FRAILTY-AVR Study","volume":"13","author":"Bendayan","year":"2020","journal-title":"JACC Cardiovasc Interv"},{"issue":"22","key":"10.1016\/j.iccl.2024.06.003_bib64","doi-asserted-by":"crossref","first-page":"2758","DOI":"10.1016\/j.jacc.2019.09.015","article-title":"Sex differences in transfemoral transcatheter aortic valve replacement","volume":"74","author":"Vlastra","year":"2019","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"20","key":"10.1016\/j.iccl.2024.06.003_bib65","doi-asserted-by":"crossref","first-page":"2050","DOI":"10.1016\/j.jcin.2017.07.044","article-title":"Association of chronic kidney disease with in-hospital outcomes of transcatheter aortic valve replacement","volume":"10","author":"Gupta","year":"2017","journal-title":"JACC Cardiovasc Interv"},{"issue":"1","key":"10.1016\/j.iccl.2024.06.003_bib66","doi-asserted-by":"crossref","DOI":"10.1002\/ccd.28989","article-title":"Impact of bleeding after transcatheter aortic valve replacement in patients with chronic kidney disease","volume":"97","author":"Li","year":"2021","journal-title":"Cathet Cardiovasc Interv"},{"issue":"1","key":"10.1016\/j.iccl.2024.06.003_bib67","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jcin.2018.09.041","article-title":"Blood disorders in patients undergoing transcatheter aortic valve replacement: a review","volume":"12","author":"De Larochelli\u00e8re","year":"2019","journal-title":"JACC Cardiovasc Interv"},{"issue":"6","key":"10.1016\/j.iccl.2024.06.003_bib68","doi-asserted-by":"crossref","first-page":"503","DOI":"10.4244\/EIJ-D-21-01048","article-title":"Bleeding risk differences after TAVR according to the ARC-HBR criteria: insights from SCOPE 2","volume":"18","author":"Garot","year":"2022","journal-title":"EuroIntervention"},{"issue":"11","key":"10.1016\/j.iccl.2024.06.003_bib69","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1016\/j.jcin.2021.03.024","article-title":"Development and validation of a practical model to identify patients at risk of bleeding after TAVR","volume":"14","author":"Navarese","year":"2021","journal-title":"JACC Cardiovasc Interv"},{"issue":"5","key":"10.1016\/j.iccl.2024.06.003_bib70","doi-asserted-by":"crossref","first-page":"e012812","DOI":"10.1161\/CIRCINTERVENTIONS.122.012812","article-title":"Antithrombotic management after left atrial appendage closure: current evidence and future perspectives","volume":"16","author":"Mesnier","year":"2023","journal-title":"Circ Cardiovasc Interv"}],"container-title":["Interventional Cardiology Clinics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211745824000622?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211745824000622?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,9,8]],"date-time":"2024-09-08T22:55:42Z","timestamp":1725836142000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211745824000622"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10]]},"references-count":70,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,10]]}},"alternative-id":["S2211745824000622"],"URL":"https:\/\/doi.org\/10.1016\/j.iccl.2024.06.003","relation":{},"ISSN":["2211-7458"],"issn-type":[{"value":"2211-7458","type":"print"}],"subject":[],"published":{"date-parts":[[2024,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"High Bleeding Risk in Patients Undergoing Coronary and Structural Heart Interventions","name":"articletitle","label":"Article Title"},{"value":"Interventional Cardiology Clinics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.iccl.2024.06.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}